Don't knowWhat happened yesterday.
Algernon to talk Ifenprodil on Aug. 26 webcast
2020-08-25 09:09 ET - News Release
Mr. Christopher Moreau reports
ALGERNON TO PROVIDE UPDATE ON ITS IFENPRODIL IPF AND CHRONIC COUGH PHASE 2 HUMAN STUDY FEATURED ON BIOPUB WEBCAST HOSTED BY DR. KSS MD PHD
Algernon Pharmaceuticals Inc. will be providing an update on its Ifenprodil idiopathic pulmonary fibrosis (IPF) and chronic cough phase 2 human study, presented by Dr. Mark Williams, chief science officer, and special guest panellist Dr. Martin Kolb. Dr. Martin Kolb is a leading global scientific expert and clinician in the area of IPF and is the Moran Campbell Chair, Professor in Respiratory Medicine and Director of the Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
The BioPub webcast will be held Wednesday, August 26, 2020 hosted by Dr. KSS at noon EDT. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.
BioPub has been analyzing small-cap special situation biotech investments for 7 years to readers in over 40 countries.
BioPub.co Presents: Algernon Pharmaceuticals' Phase 2 IPF and Chronic Cough Study Update
When: August 26, 2020 12:00 PM EDT
Please click the link below to join the webinar:
https://us02web.zoom.us/j/85700905505 Or iPhone one-tap :
US: +13017158592, 85700905505# or +13126266799, 85700905505#
Or Telephone:
US: +1 301 715 8592 or +1 312 626 6799 or +1 346 248 7799 or +1 646 558 8656 or +1 669 900 9128 or +1 253 215 8782 Webinar ID: 857 0090 5505
International numbers available: https://us02web.zoom.us/u/kkHi2pq1W
About BioPub
BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don't get and presence at meetings others don't bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.